Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.
Ádám Gy TabákJohn AndersonPablo AschnerMinzhi LiuAramesh SaremiPeter StellaFrancisco J TinahonesCarol WyshamJuris J MeierPublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2019)
ClinicalTrials.gov: NCT02058160 (LixiLan-L trial); NCT01768559 (GetGoal Duo-2 trial). Plain language summary available for this article.